Drug intelligence / Profile preview

desmethylsertraline

Development stage: Unknown
Modality: Small Molecules
Administration: Not Applicable As It Is A Metabolite

Overview

Desmethylsertraline is an active metabolite of the antidepressant drug sertraline. It acts as a monoamine reuptake inhibitor, affecting serotonin, norepinephrine, and dopamine reuptake. This results in increased levels of these neurotransmitters in the synaptic cleft, which can enhance neurotransmitter signaling and contribute to therapeutic benefits. Desmethylsertraline is less potent than sertraline as a serotonin reuptake inhibitor but exhibits a more balanced effect across serotonin, norepinephrine, and dopamine reuptake, functioning as a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).

Other names: norsertralineN-desmethylsertralineN-demethylsertraline

Targets

DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on desmethylsertraline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on desmethylsertraline.